Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Urged To Improve “Predictability” For Orphan Drugs By Social Security Head Astrue

This article was originally published in The Pink Sheet Daily

Executive Summary

Commissioner Hamburg urged to set regular briefings on orphan drug development. Policy at the top doesn’t always translate into the “trenches,” former TKT CEO says.

You may also be interested in...



SSA Seeks Industry Help In Speeding Coverage For Orphan Drugs

Sponsors of drugs to treat disabling illnesses have an opportunity to work with the Social Security Administration to simplify eligibility determinations that could in turn make it easier for patients to obtain Medicare coverage for their treatments.

SSA Seeks Industry Help In Speeding Coverage For Orphan Drugs

Sponsors of drugs to treat disabling illnesses have an opportunity to work with the Social Security Administration to simplify eligibility determinations that could in turn make it easier for patients to obtain Medicare coverage for their treatments.

Shire Adds Two Pipeline Products With TKT Acquisition

Shire's acquisition of Transkaryotic Therapies will bring the company one Hunter Syndrome therapy candidate and one Gaucher disease therapy candidate

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel